Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review

April 2021 | 68 pages | ID: G7A3D62774BEN
GlobalData

Abstracts

Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Grifols SA (Grifols) focuses on enhancing the health and well-being of people around the world. It conducts research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. Grifols offers biological materials for clinical trials, biotechnology research, manufacturing pharmaceutical and diagnostic products. The company has plasma donation centers across the US. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers products to hospitals, pharmacies and healthcare professionals. Grifols is headquartered in Barcelona, Spain.

Grifols SA Key Recent Developments

Mar 23,2021: GigaGen to present poster at the 2021 American Association for Cancer Research (AACR) Virtual annual meeting
Mar 08,2021: Grifols fosters world's first scientific journal specialized in blood plasma
Feb 26,2021: Grifols increases its revenues to 5,340 M€ and continues to demonstrate its resilience and commitment to sustainable growth
Sep 08,2020: Grifols to acquire biotech company Alkahest for $146m
Aug 10,2020: ICU Medical broadens its non-PVC/Non-DEHP IV solutions portfolio by entering long-term U.S. distribution agreement with Grifols for certain Core IV solution products

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Grifols SA - Key Facts
Grifols SA - Key Employees
Grifols SA - Key Employee Biographies
Grifols SA - Major Products and Services
Grifols SA - History
Grifols SA - Company Statement
Grifols SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Affiliate

SECTION 2 – COMPANY ANALYSIS

Company Overview
Grifols SA - Business Description
Business Segment: Bio Supplies
Overview
Performance
Business Segment: Bioscience
Overview
Performance
Business Segment: Diagnostic
Overview
Performance
Business Segment: Hospital
Overview
Performance
Business Segment: Others
Overview
Performance
Geographical Segment: European Union
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: Spain
Performance
Geographical Segment: USA and Canada
Performance
R&D Overview
Grifols SA - SWOT Analysis
SWOT Analysis - Overview
Grifols SA - Strengths
Grifols SA - Weaknesses
Grifols SA - Opportunities
Grifols SA - Threats
Grifols SA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Grifols SA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 23, 2021: GigaGen to present poster at the 2021 American Association for Cancer Research (AACR) Virtual annual meeting
Mar 08, 2021: Grifols fosters world's first scientific journal specialized in blood plasma
Feb 26, 2021: Grifols increases its revenues to 5,340 M€ and continues to demonstrate its resilience and commitment to sustainable growth
Sep 08, 2020: Grifols to acquire biotech company Alkahest for $146m
Aug 10, 2020: ICU Medical broadens its non-PVC/Non-DEHP IV solutions portfolio by entering long-term U.S. distribution agreement with Grifols for certain Core IV solution products
Jul 27, 2020: Results of Grifols' AMBAR clinical trial published in Alzheimer's & Dementia: The Journal of The Alzheimer's Association
Jul 21, 2020: Grifols to acquire GC Pharma's plasma fractionation facility for $460m
Mar 27, 2020: Grifols and Shanghai RAAS close their strategic alliance in China
Mar 26, 2020: Grifols teams up with US to test plasma therapy for Covid-19
Mar 25, 2020: Grifols announces formal collaboration with US Government to produce the first treatment specifically targeting COVID-19

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Grifols SA, Key Facts
Grifols SA, Key Employees
Grifols SA, Key Employee Biographies
Grifols SA, Major Products and Services
Grifols SA, History
Grifols SA, Other Locations
Grifols SA, Subsidiaries
Grifols SA, Affiliate
Grifols SA, Key Competitors
Grifols SA, Ratios based on current share price
Grifols SA, Annual Ratios
Grifols SA, Annual Ratios (Cont...1)
Grifols SA, Annual Ratios (Cont...2)
Grifols SA, Interim Ratios
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Grifols SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Grifols SA, Performance Chart (2016 - 2020)
Grifols SA, Ratio Charts
Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021